Therapeutic drug monitoring (TDM) could be helpful in oral targeted therapies. Data are sparse to evaluate its impact on treatment management. This study aimed to determine a threshold value of plasma drug exposure associated with the occurrence of grade 3-4 toxicity, then the potential impact of TDM on clinical decision. Consecutive outpatients treated with sunitinib were prospectively monitored between days 21 and 28 of the first cycle, then monthly until disease progression. At each consultation, the composite AUC Ƭ,ss (sunitinib + active metabolite SU12662) was assayed. The decisions taken during each consultation were matched with AUC Ƭ,ss and compared to the decisional algorithm based on TDM. A total of 105 cancer patients and 288 consultations were matched with the closest AUC Ƭ,ss measurement. The majority (60%) of the patients had metastatic renal clear-cell carcinoma (mRCC). Fifty-five (52%) patients experienced grade 3-4 toxicity. Multivariate analysis identified composite AUC Ƭ,ss as a parameter independently associated with grade 3-4 toxicity (P < 0.0001). Using the ROC curve, the threshold value of composite AUC Ƭ,ss predicting grade ≥3 toxicity was 2150 ng/mL/h (CI 95%, 0.6-0.79%; P < 0.0001). At disease progression in patients with mRCC, AUC Ƭ,ss tended to be lower than the one assayed during the first cycle (1678 vs. 2004 ng/mL/h, respectively, P = 0.072). TDM could have changed the medical decision for sunitinib dosing in 30% of patients at the first cycle of treatment, and in 46% of the patients over the whole treatment course. TDM is routinely feasible and may both contribute to improve toxicity management and to identify sunitinib underexposure at the time of disease progression.
A B S T R A C T
Therapeutic drug monitoring (TDM) could be helpful in oral targeted therapies. Data are sparse to evaluate its impact on treatment management. This study aimed to determine a threshold value of plasma drug exposure associated with the occurrence of grade 3-4 toxicity, then the potential impact of TDM on clinical decision. Consecutive outpatients treated with sunitinib were prospectively monitored between days 21 and 28 of the first cycle, then monthly until disease progression. At each consultation, the composite AUC Ƭ,ss (sunitinib + active metabolite SU12662) was assayed. The decisions taken during each consultation were matched with AUC Ƭ,ss and compared to the decisional algorithm based on TDM. A total of 105 cancer patients and 288 consultations were matched with the closest AUC Ƭ,ss measurement. The majority (60%) of the patients had metastatic renal clear-cell carcinoma (mRCC). Fifty-five (52%) patients experienced grade 3-4 toxicity. Multivariate analysis identified composite AUC Ƭ,ss as a parameter independently associated with grade 3-4 toxicity (P < 0.0001). Using the ROC curve, the threshold value of composite AUC Ƭ,ss predicting grade ≥3 toxicity was 2150 ng/mL/h (CI 95%, 0.6-0.79%; P < 0.0001). At disease progression in patients with mRCC, AUC Ƭ,ss tended to be lower than the one assayed during the first cycle (1678 vs. 2004 ng/mL/h, respectively, P = 0.072). TDM could have changed the medical decision for sunitinib dosing in 30% of patients at the first cycle of treatment, and in 46% of the patients over the whole treatment course. TDM is routinely feasible and may both contribute to improve toxicity management and to identify sunitinib underexposure at the time of disease progression.
I N T R O D U C T I O N
The pharmacokinetics of oral anticancer agents is subject to large interindividual variability, especially regarding bioavailability. Moreover, 'real-life' cancer patients are frequently old and have comorbidities and polymedication. All these factors are likely to increase the risk of acute severe toxicity. Sunitinib is an oral tyrosine kinase inhibitor (TKI) approved in advanced and metastatic renal clear-cell carcinoma (mRCC) [1] , imatinib-resistant or imatinib-intolerant gastrointestinal stromal tumors (GIST) [2] , and pancreatic neuroendocrine tumors [3] . Sunitinib is currently prescribed at a fixed dose depending on the tumor type. Dose adjustments are proposed in case of severe acute toxicity. Severe adverse events in RCC patients lead to treatment delays, dose reduction, and treatment discontinuation for 49%, 51%, and 20% of patients, respectively [4] . Major efforts have been made to minimize sunitinib toxicity, mainly through the development of alternative treatment schedules to the approved 50 mg/day and 4-week on/2-week off schedule. Motzer et al. [5] reported no benefit for efficacy from a continuous dosing (37.5 mg/day) compared to the approved treatment for RCC patients. More recently, a 2-week on/ 1-week off schedule appeared as being less toxic than the 4/2 schedule [6] and revealing similar clinical anticancer activity [7] .
A target range of 50-100 ng/mL for the sum of total plasma concentrations of sunitinib and SU12662 (active metabolite) has been proposed from PK/PD data in a mouse xenograft model [8] . These results are also strengthened by PK/PD studies among patients selected for clinical trials [9, 10] . Thus, higher sunitinib exposure in plasma is associated with a better clinical efficacy but also increased risk of severe adverse events, indicating a narrow therapeutic index [11] . This PK/ PD relationship combined with the large interindividual variability in sunitinib bioavailability is a rationale for therapeutic drug monitoring (TDM) to improve clinical efficacy and safety [12, 13] . The toxicity is more likely to develop among 'real-life' patients [14] . The development of TDM appears worthwhile to take into account the clinical complexity in treating 'real-life' patients. The threshold value of plasma composite (sunitinib+SU12662) exposure predicting grade 3-4 toxicities remains to be determined in daily clinical practice.
The aim of this clinical study conducted in nonselected adult patients with solid tumors under sunitinib therapy was (i) to determine a threshold value of plasma composite (sunitinib+SU12662) exposure associated with the occurrence of grade 3-4 toxicity (ii) to evaluate the potential impact of TDM on clinical decision.
M E T H O D S

Patient selection
All consecutive adult outpatients treated with sunitinib at Cochin University Hospital (Paris, France) were identified from medical records database. Sunitinib plasma concentration was routinely measured, and all patients who had at least one available plasma composite concentration at steady state were included. Each plasma composite exposure was matched with the closest medical consultation. All patients had provided written informed consent and agreed to the blood sampling in compliance with the ethical principles of the revised Declaration of Helsinki (2008) and with French regulations.
Treatment and toxicity assessment
Patients started sunitinib at 50 mg/day for 4 weeks and 2 weeks rest or at a lower daily dose on continuous schedule according to the patient's tumor type, age, Eastern cooperative Oncology Group (ECOG) Performance Status, or comorbidities at the discretion of the attending physician. The first visit occurred between days 21 and 28 during the first cycle of treatment. Then, a routine visit occurred every 2-3 months or earlier in case of disease progression or severe toxicity. Sunitinib-related adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0. In case of grade ≥3 toxicity, the treatment was discontinued until the adverse events returned to grade 1 or to baseline. Subsequent dose reductions were left to the discretion of the attending physicians who were blind to the plasma drug assay results. Sunitinib administration was continued until disease progression, intolerable adverse events, or patient refusal.
Quantification of sunitinib and SU12662 in plasma Sunitinib and SU12662 concentrations in plasma were assayed using liquid chromatography coupled with UV-visible detection, as previously described by our group [15] . Briefly, after a liquid-liquid extraction with ethyl acetate, sunitinib, SU12662, and ranitidine (internal standard) were separated on cyanopropyl column using a simple binary mobile phase of ammonium acetate buffer (20 mM; pH 6.8) and acetonitrile (55 : 45,v/v). Samples were eluted isocratically at a flow rate of 1 mL/min. Dual wavelength mode was used, with ranitidine monitored at 255 nm, SU12662 and sunitinib at 431 nm. The interassay coefficients of analytical variability for sunitinib and SU12662 were less than 7.0% and 9.5%, respectively. The lower quantification limit for both sunitinib and SU12662 was 10 ng/mL.
Pharmacokinetic analysis
Plasma exposure to sunitinib and SU12662 was assessed between days 21 and 28 during the first cycle of treatment, then monthly. A phase I trial conducted in patients with mRCC treated with 50 mg/day of sunitinib showed that the ratio concentration at peak/ trough concentration for sunitinib is 1.64 at steady state (days 28 of cycle) [10] . However, no data were available for SU12662. The mean half-life of sunitinib and SU12662 is about 40-60 h and 80-110 h [16] , respectively. The expected ratio concentration at peak/ trough concentration for SU12662 should be lower than the one reported for sunitinib. In this context, we considered that the sampling time has a small influence on individual Bayesian estimation of the steadystate individual area under the plasma concentration time curve from 0 to 24 h (AUC Ƭ,ss ) for sunitinib and SU12662 . Therefore, a single blood sample was collected any time during the dosing interval.
A Bayesian approach was conducted to estimate AUCs,ss for sunitinib and SU12662. Based on the results of a pharmacokinetic meta-analysis of sunitinib and SU12662 [9] , a two-compartment model with first-order absorption and elimination, as well as population values for pharmacokinetic parameters (clearance, distribution volume) and covariables such as gender, Asian race, total body weight, ECOG, tumor type were implemented in ADAPT software (University of South California, https://bmsr.usc.edu/software/ada pt/). From this population pharmacokinetic model and the individual data from each patient (plasma concentration, blood sampling time, covariables, and daily dosing), a Bayesian estimation could be performed to predict individual AUC Ƭ,ss for sunitinib and SU12662. The composite AUC Ƭ,ss was defined as the sum of sunitinib and SU12662 AUC Ƭ,ss .
Statistical analysis
Statistical analyses were performed on two sets of patients: the whole set of patients (n = 105) and the subset of patients with mRCC (n = 63). Descriptive statistics used numbers (percentages) for qualitative variables and median [interquartile range] for quantitative ones. Baseline characteristics for each group were compared using Student's t-test for continuous variables or Chi-squared or Fischer's Exact test for categorical variables. The composite AUC Ƭ,ss closest to the onset of grade 3-4 toxicity was used for the assessment of exposure-toxicity relationship. The identification of toxicity risk factors was based on logistic mixed models, with the patient effect as random effect, and one of several potential risk factors as fixed effects. In a first step, a univariate analysis was performed, with only one potential risk factor included in each model. In a second step, the significant variables (P value < 0.10) in the univariate analysis were included in a forward stepwise selection. Variables with a Wald P value lower than 0.05 were retained in the final logistic model. Receiver operating characteristic (ROC) curve was computed from the final logistic model, and threshold was determined by maximizing sensitivity + (specificity-1). Finally, sensitivity, specificity, positive and negative predictive values were computed using this threshold. All computations were performed with the SAS V9.3 statistical package (SAS Institute Inc., Cary, NC, USA).
A posteriori assessment of TDM benefit From our medical records, the medical decisions for each consultation were retrospectively collected and matched with the closest composite AUC Ƭ,ss measurement. To assess whether TDM could change medical decision, we investigated whether the medical decision would have been different knowing the last composite AUC Ƭ,ss . For this purpose, a composite AUC Ƭ,ss target range was defined: 1200-2150 ng/mL/h. The upper limit of this target range was determined from the results of the present study. The lower limit was determined from data of a phase I dose-escalation study [13] , which recommended to mean target plasma concentrations over 50 ng/mL (AUC Ƭ,ss of 1200 ng/mL/h). From this target range, the following PK/PD algorithm was defined: A composite AUC Ƭ,ss below 1200 ng/mL/ h would have resulted in an increase in daily dose, except for patients experiencing grade 3-4 toxicity. On the other hand, a composite AUC Ƭ,ss above 2150 ng/ mL/h would have led to a reduction dose or temporary treatment discontinuation. If a patient had a composite AUC Ƭ,ss above 2150 ng/mL/h with a grade 3-4 toxicity, we did not consider that TDM could improve the medical decision since toxicity assessment was sufficient enough to decide on dose reduction.
R E S U L T S
Study population
From January 2009 to January 2015, 105 patients were included in our study. Patient's characteristics are summarized in Table I . Baseline characteristics between mRCC subgroup (60% of patients) and other cancers than mRCC subgroup were significantly different regarding the use of sunitinib in first line of systemic treatment (100 vs. 45%, respectively; P < 0.001) and baseline C-reactive protein above 20 mg/L (41.5 vs. 20%, respectively; P = 0.03).
At the data cutoff in July 2015, the median followup in the entire cohort (n = 105) was 13.1 months [6.5-23.2] . During the follow-up period, 77 patients (73%) experienced disease progression and 41 (39%) died. The median progression-free survival (PFS) for RCC patients was 11.4 months (Confidence Interval 95%: 7.0-14.8).
Sunitinib pharmacokinetics
Sunitinib was started at 50 mg/day in 74 patients (70%), 37.5 mg/day in 21 patients (20%), and 25 mg/ day in 10 patients (10%). A 4-week on/2-week off schedule was initially used in 79 patients (75%) and in 57 out of the 63 patients with mRCC (90%). Median sunitinib administration follow-up was 7.2 months [3.7-14.3] . At data cutoff, 21 patients (20%) were still under sunitinib.
Regarding the PK/PD relationship, 307 samples associated with medical evaluation were analyzed, with a median of two samples per patient [1] [2] [3] [4] [5] . Ninety-six patients (91%) were included in the analysis of PK/PD relationship during the first month. ng/mL/h for 25 mg/day (n = 7), 37.5 mg/day (n = 19), and 50 mg/day (n = 70), respectively ( Figure 1a ). Significant differences in baseline characteristics were observed between patients receiving a starting dose of 50 mg/ day and patients treated with a lower starting dose: > 70 years old (18 vs. 42%, P = 0.003), women (25 vs. 65%, P < 0.0001), ECOG PS ≥ 2 (18 vs. 42%, P = 0.003), no RCC cancer (26 vs. 74%, P < 0.0001). The interindividual variability in composite AUC Ƭ,ss was large regardless the starting dose and the tumor type. Interestingly, the median dose-normalized composite AUC Ƭ,ss remained stable over the treatment course (Figure 1b) . Thus, 46 patients initially treated at 50 mg/day exhibited a similar dose-adjusted composite AUC Ƭ,ss at the first month and the sixth month (median composite AUC Ƭ,ss 2016 ng/mL/h [1518-2722] vs. 2215 [1490-2844], respectively; paired t-test P = 0.5).
Risk factors associated with sunitinib-induced grade 3-4 toxicities
Fifty-five out of 105 patients (52%) experienced grade 3-4 toxicity over the treatment course. Eighty-two episodes of grade 3-4 toxicity were recorded with a median onset of 55 days . Most of them occurred after 6 weeks (49 events vs. 33), except mucitis and cytopenia ( Figure 2) . Grade 3-4 toxicity resulted in dose reduction for 43 patients (41%) and definitive discontinuation for 15 patients (18% of 84 patients who discontinued sunitinib). Overall, 71 consultations (40 for patients with mRCC) with grade 3-4 and 217 consultations (150 for patients with mRCC) without any grade 3-4 toxicity were analyzed. Regarding risk factors (Table II) , multivariate analysis showed that grade 3-4 toxicity was independently associated with Drug monitoring and toxicity with sunitinib composite AUC Ƭ,ss (P < 0.0001), gender (P = 0.01), and tumor type (P = 0.0056) in the whole cohort and only with the composite AUC Ƭ,ss (P = 0.0006) in patients with mRCC.
Threshold value of composite AUC Ƭ,ss predicting grade 3-4 toxicity in patients with mRCC Given composite AUC Ƭ,ss was the unique parameter independently associated with grade 3-4 toxicity in RCC patients, we could determine a threshold value for developing grade ≥ 3 toxicity. Using the ROC curve, the composite AUCs,ss was 2150 ng/mL/h, and the area under the curve was 0.69 (CI 95%, 0.60-0.79; P < 0.0001). Considering this threshold value, the sensitivity, specificity, positive predictive value and negative predictive value were 65%, 76%, 42%, 89%, respectively. Median PFS in patients with mRCC (n = 60) was not statistically longer in patients with a composite AUC Ƭ,ss within cycle 1 above 2150 ng/mL/h compared to those with composite AUC Ƭ,ss below 2150 ng/mL/h (14.8 months (CI 95% 2.7-26.9) vs. 11.4 (CI 95% 5.8-17.0), P = 0.45). Median composite AUC Ƭ,ss at time of progression in 33 patients with mRCC tended to be lower than the one assayed during the first cycle of treatment (1678 [28-169] vs. 2004 [1633-2540] ng/mL/h, respectively; paired t-test, P = 0.072).
Clinical utility of TDM in the management of sunitinib therapy According to our PK/PD algorithm, we identified 42/ 105 patients (40%) for whom the medical decision at any time during sunitinib treatment would have been different knowing the last composite AUC Ƭ,ss . Noteworthy, TDM would have changed the medical decision in 28 patients (27%) at the time of the first medical evaluation. In patients with mRCC, 12 patients (19%) exhibited a subtherapeutic composite AUC Ƭ,ss without severe toxicity and could have had a dose increase. Fourteen patients (22%) had a supratherapeutic composite AUC Ƭ,ss without grade 3-4 toxicity and could have had a dose decrease, while three patients (5%) would have successively needed a dose increase and a dose reduction. Relevance of the composite AUC Ƭ,ss of sunitinib to predict early and late toxicity in patients with mRCC Figure 3 presents the occurrence of grade 3-4 toxicity in patients with mRCC (n = 60) according to early composite AUC Ƭ,ss assayed during the first month of treatment. An initial composite AUC Ƭ,ss > 2150 ng/ mL/h was more frequently associated with grade 3-4 toxicity. Among RCC patients, 50% had an initial composite AUC Ƭ,ss outside the target range (1200-2150 ng/mL/h), most of the time higher than expected. Forty percent of patients with mRCC had a composite AUC Ƭ,ss > 2150 ng/mL/h during the first cycle, and 67% of them experienced grade 3-4 toxicity. Conversely, half of the patients exhibiting a AUC Ƭ,ss below 1200 ng/mL/h experienced early disease progression. Overall, medical decision would have been changed for at least 30% of the patients at the first consultation.
D I S C U S S I O N
The issue of risk assessment and toxicity management is rapidly emerging in oncology for the treatment of cancer patients under oral therapies. This may appear paradoxical since the targeted anticancer therapies are usually seen as better tolerated than cytotoxic chemotherapy. However, the oral route introduces more unpredictability since oral anticancer agents are usually associated with a large variability in absorption and in metabolism, both resulting in a large interindividual variability in their bioavailability. Of course, the question of bioavailability of the anticancer agent does not exist with the intravenous route. Moreover, the cancer patient population is rapidly changing over decades and appears as being more fragile than the population of the clinical trials. Patients in real life are frequently old, with other concomitant chronic diseases such as cardiovascular disease or diabetes, and therefore also may be under polymedication. One response to the large interindividual variability in the bioavailability in the oral anticancer agents is TDM. Here, relying on a very broadly used targeted therapy (sunitinib), we show that TDM is likely to both improve toxicity management and detect underexposed patients whom disease progression is related to infraoptimal delivery and not to a pharmacological drug resistance. Toxicity management is a difficulty for the use of sunitinib. For this reason, several schedules have been developed. Besides, different studies showed a PK/ PD relationship between plasma sunitinib exposure and toxicity such as asthenia, thrombocytopenia [17] [18] [19] , suggesting that TDM may be helpful to optimize the management of sunitinib therapy. However, a threshold value of plasma composite exposure to predict the onset of these toxicities is currently lacking. In the Drug monitoring and toxicity with sunitinib present study, grade 3-4 toxicity was chosen as clinical endpoint because a dose reduction or treatment discontinuation always results from their occurrence. Our study is the first to propose a threshold value (2150 ng/mL/h) based on a clinical practice cohort to prevent the occurrence of grade 3-4 toxicity. Our study highlights that TDM has a real clinical relevance since it could have changed the medical decision for sunitinib dosing in almost half of the patients with mRCC. Interestingly, the need for a dose adjustment would have concerned 30% of the patients at the first consultation. However, a prospective evaluation of this threshold is warranted in a large cohort of patients before making any definitive comment about this proportion of patients. Severe sunitinib-induced acute toxicities can impact the quality of life and lead to early treatment discontinuation. The present study shows a high rate of grade 3-4 toxicity (52%) in a non-selected, real-life cohort of cancer patients. The retrospective design of our study could result in underestimation of the rate of these toxicities. The majority (60%) of grade 3-4 sunitinibinduced acute toxicities occurred after 6-week timeframe of treatment. We found similar rates of treatment discontinuation and dose reduction than those reported in phase III trials [4] , although 29% of our patients started sunitinib at a lower daily dose because of comorbidities.
As previously reported [9] , we found a large interindividual variability in sunitinib pharmacokinetics. The observed absolute composite AUC Ƭ,ss was not dependent on the starting dose, pointing out that the dose is not expected to be sufficient enough to predict sunitinib tolerability. The subgroup of patients with 25-37.5 mg/day exhibited demographic and clinical characteristics which could contribute to higher plasma exposure than expected. This subgroup of patients mainly included women. Given plasma composite exposure is known to be inversely correlated to LBM, the lower LBM in women may partly explain the increased dose-normalized exposure in this subgroup [18] . Additionally, age, ECOG PS ≥2, and advanced disease are some of the other factors that could also contribute to a lower metabolic clearance of sunitinib and SU12662 in this subgroup of patients. In contrast with other TKIs such as sorafenib and imatinib [20, 21] , the present study shows for the first time that the plasma exposure for sunitinib and SU12662 does not statistically decrease over time, indicating a low intraindividual variability in their pharmacokinetics. A recent study documented a significant intraindividual variability (CV > 25%) in 33% of patients with mRCC treated with sunitinib [22] . The pharmaceutical evaluation of comedications at each medical visit could explain in part the lower intraindividual variability observed in the present study. Overall, the present study shows that sunitinib meets all the criteria (PK/PD relationship, large interindividual variability, and low intraindividual variability) necessary for TDM.
One challenge for TDM now is to determine a composite AUC Ƭ,ss target range for the development of a dose-adaptation strategy. In literature, a target range of 50-100 ng/mL for trough composite plasma concentrations is commonly proposed [10] . Extrapolation of these trough concentrations would correspond with composite AUC Ƭ,ss of 1200-2400 ng/mL/h. Our value of 2150 ng/mL/h is lower than the one proposed in literature, probably because our patients with mRCC were at higher risk of severe toxicities (around 22% patients >70 years old and 24% patients with ECOG PS ≥ 2). Different PK/PD studies for TKIs such as erlotinib [23] and sorafenib [24] failed to show any relationship between PFS and plasma drug exposure, illustrating that determinants of response to TKIs are multifactorial. In the present study, composite AUC Ƭ,ss at time of progression in patients with mRCC tended to The mRCC population was dichotomized into two groups according to the threshold value of composite AUC Ƭ,ss predicting grade ≥ 3 toxicity (2150 ng/mL/h). The composite AUC Ƭ,ss corresponds to the AUC Ƭ,ss assayed during the first cycle of treatment. CI95%, confidence interval 95%; n, number of patients; OR, odds ratio.
be lower than the one assayed during the first month of treatment, although not statistically significantly. This decrease in composite AUC Ƭ,ss was probably related to dose reduction resulting from severe toxicity over the treatment course. Finally, a first composite AUC Ƭ,ss ≥ 2150 ng/mL/h in patients with mRCC was not associated with a longer PFS. Further investigations are warranted to determine the active target plasma concentrations in patients with mRCC.
The delayed onset of severe toxicities in our study indicates that TDM should be further benefit for patients after 6-week time frame of treatment. Sabanathan et al. [22] recently showed that the composite plasma exposure rose over time in a subset of patients with mRCC treated with a stable dose of sunitinib, which supports both an increased risk of severe toxicities over time in these patients and the need to frequently monitor their systemic exposure to prevent their onset. Even if TDM could not be useful to prevent the onset of severe toxicities during the first cycle of treatment, we believe that TDM should be started from the first cycle and thereafter continued. Herein, the use of TDM at early stage might contribute to identify patients at high risk for toxicities (composite AUC Ƭ, ss > 2150 ng/mL/h) for whom a decrease in daily dose should be discussed for the next cycle of treatment before the onset of severe toxicities. Besides, a recent pilot study also showed that increasing dose of sunitinib with TDM is feasible for patients with advanced solid tumors [25] . This suggests that a lower starting dose associated with TDM could be a reasonable way to prevent severe toxicities in frail patients, regardless of tumor type. Nevertheless, 9/21 patients (43%) who experienced grade ≥ 3 toxicity during the first cycle of treatment exhibited a composite AUC Ƭ,ss below 2150 ng/mL/h, suggesting that the toxicity is not always dependent on composite plasma level. In this specific situation, the TDM strategy is not satisfactory enough to predict the development of severe toxicities. However, it provides valuable information at the time of toxicity by proving that toxicity does not depend on the systemic exposure. In this context, switching to 2/ 1 schedule or other TKIs such as pazopanib may be a more reasonable alternative than decreasing the dose with a risk of insufficient antitumor effect.
The 2/1 schedule has been proposed instead of the recommended 4/2 schedule to prevent toxicities in patients with mRCC [6] . Recently, the RESTORE trial has reported a similar efficacy between the two schedules in treatment-naive Asian patients with mRCC [7] .
In the present study, no patients were treated with 2/1 schedule. By contrast, a 4/2 schedule vs. a continuous schedule was not identified as an independent risk factor for developing grade 3-4 toxicity, while composite AUC Ƭ,ss was independently associated with grade 3-4 toxicity. Altogether, these results suggest that TDM could be helpful to optimize the clinical management of patients regardless of dosing schedule (4/2 schedule, continuous daily schedule) before switching to 2/1 schedule. Finally, the large interindividual variability in sunitinib pharmacokinetics suggests that TDM could also be helpful regardless the drug administration schedule.
The benefit of TDM for TKIs remains currently unknown. However, TDM is recommended for specific situations such as lack of response, severe toxicities, pharmacokinetic drug-drug interactions, and concerns about over adherence treatment [13] . As far as we know, a single comparative randomized trial of recommended dosing vs. TDM was carried out in chronic myelogenous leukemia patients under imatinib [26] . The negative results of the imatinib study were probably due to the small number of patients included and the non-respect of dosage recommendations for a significant number of prescribers. Nevertheless, patients for whom dosing was adjusted according to the PK/PD algorithm had favorable outcomes [26] . Recently, Sabanathan et al. [22] compared TDM and toxicity-adjusted dose (TAD) in patients with mRCC with adjustment of sunitinib daily dose to achieve grade 1-2 toxicity on 10-20 days of each 42-day cycle. Interestingly, this study shows both the feasibility of TAD and favorable outcomes for sunitinib dose individualization. Nevertheless, this study also points out that TDM would be necessary in some patients with mRCC. Indeed, 15% of patients exhibited plasma composite concentration above 100 ng/mL, which could result in the onset of severe toxicity without additional efficacy. Finally, as previously mentioned, a substantial intraindividual variability in composite plasma concentrations (>25%) was observed in 33% of the patients. Overall, these results suggest that combining TAD with TDM could be a promising way to optimize sunitinib dose individualization. A clinical trial is currently undergoing to prospectively evaluate this approach (ANZCTR identifier number: ACTRN 2616001639415). The design of the present study does not allow concluding on the benefit of TDM for sunitinib. Our threshold value for developing grade ≥ 3 toxicity could be used in future comparative randomized trials of recommended dosing vs. TDM for sunitinib. Drug monitoring and toxicity with sunitinib
In conclusion, our study suggests that sunitinib TDM could be helpful in daily clinical practice. Additionally, we encourage to early perform this TDM over the treatment course. Finally, most of the new targeted therapies share the oral route and a large interindividual variability in their bioavailability with sunitinib. In this context, we recommend to early introduce a robust PK/PD approach in drug development during clinical trials to be able to optimize the treatment management of targeted therapies in a personalized manner through TDM.
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